Bernstein analyst Nadine Sarwat downgrades Boston Beer Co (NYSE:SAM) from Market Perform to Underperform and lowers the price target from $320 to $255.
Why Is Blindness Focused-Adverum Biotechnologies Stock Trading Lower Today?
Adverum Biotechnologies' Ixo-vec gene therapy for wet AMD. Preliminary LUNA Phase 2 trial data show safety, efficacy, and significant treatment burden reduction.